IP Library › Granted Patent US 12,383,608
Granted Patent B2
US 12,383,608 · App. 16/464,950 · Granted Aug 12, 2025

WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides

Inventors: Hitoshi Ban (Nishinomiya, JP); Masashi Goto (Ibaraki, JP); Yosuke Takanashi (Osaka, JP)
Assignees: SUMITOMO PHARMA CO., LTD.; INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
A61K39/001153A61K39/00A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,608
App. No.
16/464,950
Granted
Aug 12, 2025
Kind
B2
Abstract

The present application relates to WT1 helper peptides consisting of an amino acid sequence of 9 to 30 amino acid residues including a sequence: KLSHL as part thereof, and combinations of a WT1 helper peptide and a conjugate of cancer antigen peptides.

Claims (214)

1. A composition or kit comprising at least one compound selected from the compound of formula (3):

or a pharmaceutically acceptable salt thereof, or a compound of formula (4):

or a pharmaceutically acceptable salt thereof,

wherein C—C are linked together by disulfide bond,

and

cancer antigen peptide D or a pharmaceutically acceptable salt thereof, wherein the cancer antigen peptide D is a peptide which induces WT1-specific helper T cells by binding to an MHC class II molecule and consisting of the amino acid sequence selected from:

(SEQ ID NO: 2)

AYPGCNKRYFKLSHL,

(SEQ ID NO: 3)

YPGCNKRYFKLSHLQ,

(SEQ ID NO: 8)

NKRYFKLSHLQMHSRK,

(SEQ ID NO: 9)

KRYFKLSHLQMHSRK,

(SEQ ID NO: 11)

RYFKLSHLQMHSRKH,

(SEQ ID NO: 12)

YFKLSHLQMHSRKHT,

(SEQ ID NO: 13)

FKLSHLQMHSRKHTG,

(SEQ ID NO: 14)

KLSHLQMHSRKHTGE,

(SEQ ID NO: 39)

RYFKLSHLQMHSRK,

(SEQ ID NO: 40)

YFKLSHLQMHSRK,

(SEQ ID NO: 41)

FKLSHLQMHSRK,

(SEQ ID NO: 42)

KLSHLQMHSRK,

(SEQ ID NO: 43)

AYPGCNKRYFKLSHLQMH,

(SEQ ID NO: 44)

AYPGCNKRYFKLSHLQMHSRK,

(SEQ ID NO: 45)

RYFKLSHLQMH,

(SEQ ID NO: 46)

GCNKRYFKLSHL,

(SEQ ID NO: 47)

FKLSHLQMHSRKHTGE,

(SEQ ID NO: 48)

RYFKLSHLQMHSRKHT,

(SEQ ID NO: 49)

RYFKLSHLQMHSRKHTGE,

(SEQ ID NO: 50)

KLSHLQMHSRKH,

(SEQ ID NO: 52)

AYPGCNKRYFKLSHLQMHSR,

(SEQ ID NO: 53)

AYPGCNKRYFKLSHLQMHS,

(SEQ ID NO: 54)

AYPGCNKRYFKLSHLQM,

(SEQ ID NO: 55)

AYPGCNKRYFKLSHLQ,

(SEQ ID NO: 56)

YFKLSHLQMHSRKHTGE,

(SEQ ID NO: 57)

RYFKLSHLQMHSRKHTG,

(SEQ ID NO: 58)

RYFKLSHLQMHSR,

(SEQ ID NO: 59)

RYFKLSHLQMHS,

(SEQ ID NO: 60)

RYFKLSHLQM,

(SEQ ID NO: 61)

YPGCNKRYFKLSHL,

(SEQ ID NO: 62)

PGCNKRYFKLSHL,

(SEQ ID NO: 63)

CNKRYFKLSHL,

(SEQ ID NO: 64)

NKRYFKLSHL,

(SEQ ID NO: 65)

KLSHLQMHSRKHTG,

(SEQ ID NO: 66)

KLSHLQMHSRKHT,

and

(SEQ ID NO: 67)

KLSHLQMHSRK,

or a peptide consisting of the amino acid sequence that differs from the amino acid sequence of the cancer antigen peptide D by alteration of one amino acid residue, provided that the cancer antigen peptide D is not SEQ ID NO:6, SEQ ID NO: 7, SEQ ID NO: 10, SEQ ID NO: 38, or SEQ ID NO:51.

2. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (3):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof.

3. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof.

4. The composition or kit according to claim 1 , wherein the cancer antigen peptide D is a peptide consisting of the amino acid sequence selected from:

(SEQ ID NO: 2)

AYPGCNKRYFKLSHL,

(SEQ ID NO: 3)

YPGCNKRYFKLSHLQ,

(SEQ ID NO: 8)

NKRYFKLSHLQMHSRK,

(SEQ ID NO: 9)

KRYFKLSHLQMHSRK,

(SEQ ID NO: 11)

RYFKLSHLQMHSRKH,

(SEQ ID NO: 12)

YFKLSHLQMHSRKHT,

(SEQ ID NO: 13)

FKLSHLQMHSRKHTG,

and

(SEQ ID NO: 14)

KLSHLQMHSRKHTGE.

5. The composition or kit according to claim 1 , wherein the cancer antigen peptide D is a peptide consisting of the amino acid sequence selected from:

(SEQ ID NO: 39)

RYFKLSHLQMHSRK,

(SEQ ID NO: 40)

YFKLSHLQMHSRK,

(SEQ ID NO: 41)

FKLSHLQMHSRK,

(SEQ ID NO: 42)

KLSHLQMHSRK,

(SEQ ID NO: 43)

AYPGCNKRYFKLSHLQMH,

(SEQ ID NO: 44)

AYPGCNKRYFKLSHLQMHSRK,

(SEQ ID NO: 45)

RYFKLSHLQMH,

(SEQ ID NO: 46)

GCNKRYFKLSHL,

(SEQ ID NO: 47)

FKLSHLQMHSRKHTGE,

(SEQ ID NO: 48)

RYFKLSHLQMHSRKHT,

(SEQ ID NO: 49)

RYFKLSHLQMHSRKHTGE,

(SEQ ID NO: 50)

KLSHLQMHSRKH,

(SEQ ID NO: 52)

AYPGCNKRYFKLSHLQMHSR,

(SEQ ID NO: 53)

AYPGCNKRYFKLSHLQMHS,

(SEQ ID NO: 54)

AYPGCNKRYFKLSHLQM,

(SEQ ID NO: 55)

AYPGCNKRYFKLSHLQ,

(SEQ ID NO: 56)

YFKLSHLQMHSRKHTGE,

(SEQ ID NO: 57)

RYFKLSHLQMHSRKHTG,

(SEQ ID NO: 58)

RYFKLSHLQMHSR,

(SEQ ID NO: 59)

RYFKLSHLQMHS,

(SEQ ID NO: 60)

RYFKLSHLQM,

(SEQ ID NO: 61)

YPGCNKRYFKLSHL,

(SEQ ID NO: 62)

PGCNKRYFKLSHL,

(SEQ ID NO: 63)

CNKRYFKLSHL,

(SEQ ID NO: 64)

NKRYFKLSHL,

(SEQ ID NO: 65)

KLSHLQMHSRKHTG,

(SEQ ID NO: 66)

KLSHLQMHSRKHT,

and

(SEQ ID NO: 67)

KLSHLQMHSRK.

6. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: AYPGCNKRYFKLSHL (SEQ ID NO: 2) or a pharmaceutically acceptable salt thereof.

7. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: YPGCNKRYFKLSHLQ (SEQ ID NO: 3) or a pharmaceutically acceptable salt thereof.

8. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: NKRYFKLSHLQMHSRK (SEQ ID NO: 8) or a pharmaceutically acceptable salt thereof.

9. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: KRYFKLSHLQMHSRK (SEQ ID NO: 9) or a pharmaceutically acceptable salt thereof.

10. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: RYFKLSHLQMHSRKH (SEQ ID NO: 11) or a pharmaceutically acceptable salt thereof.

11. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: YFKLSHLQMHSRKHT (SEQ ID NO: 12) or a pharmaceutically acceptable salt thereof.

12. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: FKLSHLQMHSRKHTG (SEQ ID NO: 13) or a pharmaceutically acceptable salt thereof.

13. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: KLSHLQMHSRKHTGE (SEQ ID NO: 14) or a pharmaceutically acceptable salt thereof.

14. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: RYFKLSHLQMHSRK (SEQ ID NO: 39) or a pharmaceutically acceptable salt thereof.

15. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: AYPGCNKRYFKLSHLQMH (SEQ ID NO: 43) or a pharmaceutically acceptable salt thereof.

16. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: AYPGCNKRYFKLSHLQMHSRK (SEQ ID NO: 44) or a pharmaceutically acceptable salt thereof.

17. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: RYFKLSHLQMH (SEQ ID NO: 45) or a pharmaceutically acceptable salt thereof.

18. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: GCNKRYFKLSHL (SEQ ID NO: 46) or a pharmaceutically acceptable salt thereof.

19. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: RYFKLSHLQMHSRKHT (SEQ ID NO: 48) or a pharmaceutically acceptable salt thereof.

20. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof is the compound of formula (4):

wherein C—C shown in the formula means that the C residues are linked together by a disulfide bond,

or a pharmaceutically acceptable salt thereof, and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof is a peptide consisting of the amino acid sequence: RYFKLSHLQMHSRKHTGE (SEQ ID NO: 49) or a pharmaceutically acceptable salt thereof.

21. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof are formulated in separate compositions.

22. The composition or kit according to claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof and the cancer antigen peptide D or a pharmaceutically acceptable salt thereof are incorporated in a single composition.

23. The composition or kit according to claim 1 , wherein the cancer antigen peptide D is a peptide which induces WT1-specific helper T cells by binding to an MHC class II molecule selected from the group consisting of DRB1*0101, DRB1*0405, DRB1*0802, DRB1*0803, DRB1*0901, DRB1*1201, DRB1*1403, DRB1*1501, DRB1*1502, DPB1*0201, DPB1*0202, DPB1*0402, DPB1*0501, DPB1*0901, DQB1*0301, DQB1*0302, DQB1*0401, DQB1*0501, DQB1*0601, DQB1*0602, and DRB5*0102.

24. The composition or kit according to claim 1 , wherein the cancer antigen peptide D is a peptide which induces WT1-specific helper T cells by binding to an MHC class II molecule selected from the group consisting of DRB1*0101, DRB1*0405, DRB1*1502, DPB1*0201, DPB1*0202 and DQB1*0601.

25. A pharmaceutical composition comprising the composition according to claim 1 , and a pharmaceutically acceptable carrier.

26. The composition or kit according to claim 1 , wherein the composition or kit is the composition.

27. The composition or kit according to claim 1 , wherein the composition or kit is the kit.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2025
From: SUMITOMO PHARMA CO., LTD.
To: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Reel/Frame 072160/0981 →
CHANGE OF NAME Recorded Jun 10, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 060161/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 29, 2019
From: BAN, HITOSHI; GOTO, MASASHI; TAKANASHI, YOSUKE
To: SUMITOMO DAINIPPON PHARMA CO., LTD.; INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.
Reel/Frame 049308/0264 →